New Companies
Filter News
Found 3,552 articles
-
ArsenalBio will focus on integrating various technologies, including CRISPR, synthetic biology, and machine learning to discover and develop immunotherapies, initially for oncology.
-
Adaptate will build on GammaDelta’s expertise in modulating gammadelta T-cell activity using antibodies, with a focus on developing an immune response to cancer.
-
Ichnos Sciences Launches as New, Independent, Leading-Edge Biotech Dedicated to Outpacing Disease
10/15/2019
Ichnos ('īk-nōz) Sciences officially opened its doors to the world today as an independent, fully integrated, global biotech company
-
Minnesota Mix of Skilled Med Device Workforce and Clinical Partnerships Propels Abilitech™ Medical
10/15/2019
Abilitech wins 2019 MN Cup on its way to TEKNE competition, FDA registration prep and 75-patient clinical study
-
SHINE Creates Therapeutics Division, Will Attend 2019 European Association of Nuclear Medicine Conference
10/11/2019
SHINE Medical Technologies, LLC today announced the creation of a new division of the company — SHINE Therapeutics
-
Cygnal was founded in 2017 based on discoveries made in the field of exoneural biology, which is a new understanding of how nerves and neural signaling drive human health and disease.
-
Flagship Pioneering Unveils Cygnal Therapeutics
10/8/2019
Company is Developing Drugs in the Field of Exoneural Biology to Address Cancer, Inflammatory Disease, and More [08-October-2019] CAMBRIDGE, Mass. , Oct. 8, 2019 /PRNewswire/ -- Flagship Pioneering, a unique life sciences innovation enterprise, today unveiled Cygnal Therapeutics . Founded in 2017 in Flagship Labs, Flagship's innovation foundry, Cygnal is the first co
-
Woman-owned Start-Up Creates a Brand-New Product Category That Addresses One of the Most Prevalent but Rarely Discussed Issues in Women's Health
10/7/2019
pH-D® Feminine Health has revolutionized the feminine hygiene market.
-
Fuzionaire Diagnostics Partners with Japan Medical Isotope Technology Development K.K. to Launch Fuzionaire Radioisotope Technologies K.K.
10/3/2019
Japanese affiliate to advance diagnostic and therapeutic applications of proprietary radiolabeling platform
-
Three-Company M&A Deal Creates New Clinical Trial Industry Leader, Apex Innovative Sciences, Inc.
10/2/2019
CNS Network and Hassman Research Institute have completed a strategic merger to form Apex Innovative Sciences, Inc..
-
Immunovant to Merge with Health Sciences Acquisitions Corporation, Creating New Publicly Listed FcRn-Focused Company
10/2/2019
Top shareholders of Immunovant post-closing to include Roivant Sciences and blue-chip biotech investors, including RTW Investments, BVF Partners, Adage Capital Management, Cormorant Asset Management, Eventide Asset Management, and Perceptive Advisors
-
Startup Sandbox Graduates First Class of Innovators
9/30/2019
Graduating Startups Poised to Deliver Innovation Breakthroughs with Global Impact
-
Research on Research Institute (RoRI) launches to enable more strategic, open, diverse, and inclusive research
9/30/2019
We’re proud to announce the launch of the Research on Research Institute – an international consortium of research funders, academic institutions, and technologists working to champion the latest approaches to research on research.
-
Self-Translating Pharmaceutical Labels to Disrupt Industry
9/27/2019
Context-Aware Packaging Is Just the Tip of the Iceberg Says Third Aurora
-
Company Profile for Mirum Pharmaceuticals
9/26/2019
The company’s lead product candidate, maralixibat, is an investigational oral drug in development for progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS).
-
Dana-Farber Cancer Institute and the Jimmy Fund Debut New Visual Identity
9/26/2019
Dana-Farber Cancer Institute unveiled a new visual identity, modernizing its logo and that of the Jimmy Fund with a vivid blue and gold palette.
-
Epigenetics is the study of changes in gene expression that don’t involve changes to the DNA sequence.
-
Delos Capital Announces the Launch of Curamir Therapeutics Inc. with a $10 Million Series A to Develop miRNA-based Cancer Therapeutics
9/20/2019
Delos Capital today announces that it has launched Curamir Therapeutics Inc., a Woburn, MA-based biotechnology company pioneering micro RNA (miRNA) based cancer therapeutics, with a $10 million Series A financing.
-
Noramco Cannabinoids Business to Become Purisys
9/19/2019
Two Organizations Will Build on Strengths to Address Differentiated End-Use Markets
-
INTRODUCING VERTOSA: Cannabis and Hemp Infusion Technology Company Nanogen Labs Announces Rebrand
9/18/2019
Plus Five New Hires Support Company Expansion